[go: up one dir, main page]

WO2015176848A1 - Forme posologique auto-séchante avec temps de séchage et vitesse de séchage réglables - Google Patents

Forme posologique auto-séchante avec temps de séchage et vitesse de séchage réglables Download PDF

Info

Publication number
WO2015176848A1
WO2015176848A1 PCT/EP2015/056079 EP2015056079W WO2015176848A1 WO 2015176848 A1 WO2015176848 A1 WO 2015176848A1 EP 2015056079 W EP2015056079 W EP 2015056079W WO 2015176848 A1 WO2015176848 A1 WO 2015176848A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
acid
pharmaceutically acceptable
drying
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/056079
Other languages
English (en)
Inventor
K. H. Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015176848A1 publication Critical patent/WO2015176848A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to a self -drying pharmaceutical dosage form or food product , and a process for preparing a pharmaceutical dosage form or food product, which are able to dry in situ and do not require any drying measures such as heating and which allow controlling of both the drying time and the drying rate .
  • Conventional methods for preparing a pharmaceutical dosage form comprise we mixing or wet granulation of the ac ive pharmaceutical ingredient ( s) with suitable pharmaceutical excipients and thereafter bringing the dosage form into its desired physical shape , e.g. by compression in the case of a tablet . Subsequen ly, the thus obtained mixed and wet granulated intermediate pharmaceutical dosage forms are subjec ed to physical drying, usually by heating and/or by evaporation, in order to remove excess water from the intermediate as well as from the final dosage form.
  • the present invention provides in a first aspect a process for preparing a pharmaceutical dosage form
  • Such a process allows the producing of dosage forms without any physical drying step such as heating and/or evaporation or the like .
  • the process further allows adj sting the reaction time of the drying reaction depending (a) on the choice of the water-acceptor or the ratio of CaO and MgO used as water -acceptor, (b) on the choice of the water-donor and/or (c) the addition of one or more pharmaceutically acceptable acid(s) .
  • the water-binding chemical reaction allowing the mass to dry in situ is conducted with at least one pharmaceutically acceptable earth alkaline metal oxide selected from CaO and/or MgO, preferably a mixture of CaO and MgO, that orms , upon being contacted with water, the solid hydroxides Ca (OH) 2 and/or Mg (OH) 2 ⁇
  • the reaction of CaO with water to Ca (OH) 2 is a very rapid and exothermic reaction
  • the reaction of MgO to Mg (OH) 2 is much slower due to the ormation of a Mg (OH) 2 protective layer on the surface of the MgO, which, as a consequence significantly prolongs the complete conversion of MgO to Mg (OH) 2 ⁇
  • Removal of the protective layer allowing for a complete conversion of MgO to Mg (OH) 2 ( can be achieved by the addition of one or more pharmaceutic l acceptable acid (s) .
  • Magnesium citrate for example is able to bind high amounts of crystal water (14 mol) and thus represents a fa orable salt to optimize the chemical drying step . It can be formed in si u by reaction of MgO and citric acid in the presence of a water donor
  • the present invention provides a solid, non-porous pharmaceutical dosage form, which is a cas ing comprising (a) at least one ac ive pharmaceutical ingredient , (b) at least one pharmaceutically acceptable excipient selected from Ca (OH) 2 and Mg (OH) 2 , a hydrated metal salt of Ca and/or Mg of a pharmaceutically acceptable acid, or a mixture thereof and (c) at least one pharmaceutically acceptable excipient selected from one or more
  • the amount of water in the casting suspension is preferably in the range of 10 to 25% w/w, and more preferably in the range of 15 to 20% w/w, based on the total dosage form.
  • the amount of free or immobile water which is contained in the final pharmaceutical dosage form after the chemical drying reaction is between 0 and 5% w/w, preferably 1 -4% , more preferably 2-3% w/w.
  • the molar ratio of the water acceptors used in the inventive formulations and the water content of the water-donor (s) is between 2 : 1 and 1:4, more preferably between 1:2 and 1:1.
  • a casting according to the second aspect of the invention is obtainable by a process according to the present invention, including any preferred embodiment thereof as set forth in the appending claims .
  • the casting is obtained by using a process according to the present invention.
  • a casting suspension still containing unreacted CaO and/or MgO and syrup is poured or cast into appropriate cavities , such as moulds or the cavities of a blister pack and allowed to slowly dry so as to form the corresponding hydroxides and/or hydrated salts .
  • the main part of this drying process occurs after the casting process , e.g. by standing over night . the final (dried) casting will therefore contain
  • the drying agent is the water-acceptor selected from at least one pharmaceutically acceptable earth alkaline metal oxide selected from CaO and/or MgO.
  • the present inven ion provides the use of at least one pharmaceutically acceptable water-acceptor selected from CaO and/or MgO for preparing a self -drying pharmaceutical dosage form or food product , allowing
  • the present invention provides the use of at least one pharmaceutically acceptable water- acceptor, more preferably a mixture of CaO and MgO, and one or more pharmaceutically acceptable waterdonor selected from a syrup of one or more pharmaceutically acceptable sugar (s) , sugar alcohol (s) or salt (s ) , or mixtures thereof , and optionally one or more pharmaceutically acceptable acid ( s) for preparing a self -drying dosage form, which can be a pharmaceutical dosage form or a food product .
  • the dosage form can be a casting as described herein.
  • the present inven ion is directed to a process for preparing a pharmaceutical dosage form, which does not require and preferably does not involve any physical drying ste .
  • the drying is conducted in situ, i.e. the dosage for dries by itself , by means of a water-binding chemical reaction (“chemical drying” ) .
  • chemical drying all or at least a substan ial part (preferably at least 75 wt.%, more preferably at least 85% , even more pre erably at least 95 wt.%) of the water contained in the water-donor reacts with the water- acceptor to form either a hydroxide or a hydrate of the water- acceptor .
  • physical drying in the sense of this description a process is meant wherein excess liquid
  • composition is removed by physical means such as e.g. heating or applying reduced pressure (evaporation) , centrifugal forces or other drying technologies known to the skilled person .
  • the present invention aims to avoid such physical drying processes .
  • a “pharmaceutical dosage form” according to the present invention is a dosage form for the treatment and prevention of diseases in humans or animals .
  • compositions may thus be used in human and/or veterinary medicine .
  • a "food product” according to the present invention must be solid, edible and approvable for human and.or animal
  • food product particularly includes swee s , for example lollipops or candies .
  • Food products are distinguished from pharmaceu ical dosage forms in that, they do not contain an active pharmaceutical ingredient ' drug) . They can be prepared by the same inven ive processes as pharmaceutical dosage forms, except that the active
  • the present invention also includes in one of its aspects a process for preparing a pharmaceutical dosage form comprising the steps of
  • preparing a pourable or kneadable mass comprising (i) at least one pharmaceutically acceptable water-donor selected from a syrup of one or more pharmaceutically acceptable sugar ( s) , sugar alcohol (s) or salt (s) , or mixtures thereof , , (ii) optionally further pharmaceutically acceptable excipients, and (iii)at least one
  • the present invention also includes food products having the same composition as described in appending claims 11 - 15 , except that they do not contain an active pharmaceutical ingredient .
  • dosage form as used herein is supposed to embrace both pharmaceutical dosage forms and food products that prepared according to the present inventio .
  • a "water-binding chemical reaction" within the meaning of the invention is a chemical drying process wherein one or several pharmaceutically acceptable excipients acting as water- acceptors chemically react with and bind water .
  • this process takes place in situ and at room temperature when the water-binding drying agent is contacted with the water- donor .
  • a “chemical reaction” as used herein includes the formation of a (normally stable, crystalline) hydrate of a previously anhydrous or less strongly hydra ed form of a chemical substance .
  • pharmaceutically acceptable has the ordinary meaning and particularly includes the aspects that the excipient should be suff ciently acceptable in taste , stable under the conditions in which the use of the dosage form is intended and not cause undesirable adverse effects .
  • the excipient should be one that has been approved for pharmaceutical uses .
  • a pharmaceutically acceptable excipient in the context of an excipient characterizes a property of the excipient (i.e. the excipient must be suitable for pharmaceutical uses) , but should not be misunderstood as actually requiring such a pharmaceutical use in each and every case .
  • a pharmaceutically acceptable excipient may also be used in the preparation of a food product , such as a candy .
  • the "pharmaceutical acceptable a id" according to the present invention is an acid which has been approved for
  • the "pharmaceutical acceptable acid” is an organic acid, more preferably a fruit acid and in the most preferred embodiment citric acid .
  • the process according to the present invention as well as the casting obtained by the process of the present invention may also contain more than one "pharmaceutical acceptable acid”.
  • the "water-donor" according to the present invention is a syrup of a pharmaceutically acceptable excipient .
  • a syrup according to the present invention is a highly concentrated aqueous solution, which is both still fluid and contains relatively little water, and is highly water-soluble . The use of syrup is superior over the use of pure water, which does not allow controlling the drying time and affords a longer drying time .
  • the excipient used to form the water-donor is a pharmaceutically acceptable sugar , sugar alcohol , salt or a mixture thereof.
  • suitable excipients are sorbitol , saccharose , fructose , xylitol , glucose , fructose or mixtures thereof . Sorbitol and saccharose or a mixture thereof is particularly pre erred.
  • control of drying rate and drying time describes the possibility to fine tune the reaction time of the chemical in situ drying reaction by varying several parameters , ( 1 ) the choice of water- acceptor, i.e. either CaO or MgO or a mixture thereof , (2) the ratio of CaO and MgO if used in a mixture , (3 ) the type and amount of one or more pharmaceutically acceptable acid, and (4 ) the type and amount of the syru . In the presence of water CaO and MgO are converted to Ca (OH) 2 and Mg ⁇ OH) 2 , respectively. While CaO reacts to Ca (OH) 2 in a fast and exothermic
  • MgO reacts muc more slowly due to the forma ion of a protective layer on the MgO surface .
  • the mixture and choice of ratio of CaO and MgO as water-acce tor thus allows controlling the drying time and drying rate .
  • the drying time and drying rate is further influenced by the addition of an acid, which is able to destroy the Mg (OH) 2 protective layer, which has been formed on the surface of MgO, slowing down the reaction time.
  • the amount of added acid and the choice of acid represent a further tool to control the drying rate and drying time .
  • Highly soluble within the meaning of the present invention refers to a water solubility of at least 400 g per litre of water at 20°C.
  • a “casting”, as used herein, is a moulded, solid
  • pharmaceut ical dosage form obtained by filling a pourable or kneadable wet mass into a suitable mould, e.g. the cavities of a blister pack, and allowing it to dry . This filling process can be carried out by using appropriate dose
  • the casting according to the present invention is non-porous . i.e. is substantially free of any void spaces and has a homogenous structure when observed by a microscope, in contrast to common tablets or granulates where particular structures can still be observed.
  • the casting according to the present invention is generally prepared by a casting process wherein the homogeneous liquid or kneadable masses as described above are dispensed into moulds or blister packs , followed by chemical drying in situ .
  • Porosi y can be measured by several methods known in the art .
  • porosity can either be measured by determining the pore volume by using e.g. mercury intrusion porosimetry or fluid saturation methods or by determining the grain volume e.g. by gas expansion methods (Boyle's law porosimeter) .
  • non-porous a porosity of less than 5%, preferably 3% or less, more preferably 1% or less, still more preferably 0.5% or less , and most preferably 0% is meant, as measured by mercury porosimetry.
  • the "water-acceptor”, “drying agent” or “hydraulic binding agent”, which terms can be used interchangeably in the context of this invention is at least one pharmaceutically acceptable earth alkaline metal oxides selected from CaO and/or MgO that is able to chemically bind water and to thus allow for the in situ drying of the freshly prepared casting .
  • a mixture of CaO and MgO is used as water -accepto .
  • the water-acceptor should be used in the process according to the present invention in an amount that is sufficient to bind at least 90 wt . - % , more preferably at least 95 wt . -%, and most preferably at least 98 wt . - % of the free water contained in the dosage form .
  • Other earth alkaline metals such as Sr might be used for special applications , but only in limited and non- toxic amounts. They are generally less suitable for the purposes of the present invention .
  • Crystal water (hydrate water) is not “free water” within the meaning of the present invention, but is “bound water” and therefore remains in the pharmaceutical dosage form also after the chemical drying in situ of the dosage form.
  • "Bound water” also includes molecularly bound water: for example, Magnesium hydroxide (Mg (OH) 25 contains one molecule of molecularly bound water . Bound water cannot be removed under ordinary physical drying conditions such as by heating at 50°C .
  • the term "at least one" as used in this application includes one, two, three , four and more, preferably one or two . For example, one or two excipients are used to form the water- donor and/or the water-acceptor. Even more preferably, just one sugar, sugar alcohol or salt is combined wi h water to form a homogenous syrup ⁇ water-donor) .
  • the water-acceptor is CaO, MgO, or a mixture of these species .
  • prefe bly consist of the steps a, b and c as recited in claim 1, and the pourable or kneadable mass used therein may preferably consist only of the components (i) - ( iv) as recited in claim 1.
  • the casting according to the present invention may just consist of the components (a) , (b) and (c) as recited in the claims , but may also contain further components, for example a further pharmaceutically acceptable excipient such as at least one flavouring or colouring agent , a sweetener , an antifoaming agent , a dispersing agent or a diluent .
  • Water-binding chemical drying reactions are known per se and have been used e.g. in the building industry for centuries : By using 1 part of slaked lime (CaO) and 4 parts of water, a solidifying mortar is mixed. The corresponding hydroxides are thereby formed . They gradually convert into the respective carbonates under uptake of C0 2 from the air .
  • CaO slaked lime
  • reagents such as CaO that readily bind water are commonly referred to as hydraulic binding agents .
  • the present invention provides the use of at least one pharmaceutically acceptable hydraulic binding agents for preparing a self-drying pharmaceutical dosage form or food product selected from CaO and/or MgO, and preferably a mixture of CaO and MgO.
  • the water-binding chemical drying reaction of a water- containing pharmaceutical dosage form according to the present invention is based on the same hydraulic binding reaction: A pharmaceutically acceptable water-acceptor or a mixture of such excipients as defined above that is able to bind water is added to an aqueous pharmaceutical composition, and then the mass is allowed to dry in situ by means of water-binding chemical reactions .
  • the further conversion of the hydroxides into the corresponding carbonates by CO2 uptake is not necessary according to this invention, but is not excluded and may be a further possible embodiment of the invention.
  • the pourable or kneadable wet mass is dosed and brought into its desired shape before drying. This can easily be accomplished, for example, by casting the wet mass into suitable moulds such as the cavities (wells) of a blister packaging.
  • the drying time and drying rate of the single dosage form is such that the chemical drying starts only after completion of the dosing step, allowing to use the advantage process of the present inven ion in an industrial scale , affording dosing times of 10 hours and more .
  • the drying time and drying rate can be controlled and optimized by varying the water-acceptor, i.e. either using CaO, MgO or a mixture of these two, and by opt onally adding an acid, which depending on the kind of acid and amount added can further influence the drying time and drying reaction.
  • the amount of pharmaceutically acceptable water-acceptor that is able to bind water is added in an amount so that most of the free water (at least 90 wt.-%, preferably at least 95 wt . - % , more preferably at least 98 w . -%) present in the formulation is absorbed and transformed into molecular water or into crystal water of the pharmaceutically acceptable alkaline earth metal hydroxides and hydrates of Ca and/or Mg .
  • the free water present in the formulation may stem from the water-donor used for formulation as defined above or may be formed during e.g. the neutralisation of an earth alkaline oxide or hydroxide with a solid pharmaceutically acid, if such acid is also used for the formulation .
  • the at least one pharmaceutically acceptable alkaline earth metal oxide is CaO and/or Mg-GaO, and preferably a mixture thereof .
  • the oxide (s) should ideally be in a state that allows them to readily react with water to form the
  • a pharmaceutically acceptable acid in particular a water-free acid, can be used in the present invention to form the pourable or kneadable mass th t is then allowed to dry in situ.
  • a pharmaceutically acceptable acid is particularly advantageous if MgO is used as a drying agent alone or in a mixture with CaO, since magnesium oxide forms a protecting layer of Mg (OH) 2 upon contact with water. Using an acid helps to destroy this protecting layer and to enable the reaction of MgO with water to continue . Without the use of an acid the chemical drying reaction would take much longer.
  • the pharmaceutically acceptable acid is preferably water-free and can mainly be selected e.g. from citric acid, glacial acetic acid, phosphoric acid, tartaric acid, malic acid, fumaric acid, adipinic acid, ascorbinic acid and raaleic acid or mixtures thereof .
  • citric acid glacial acetic acid
  • phosphoric acid tartaric acid
  • malic acid fumaric acid
  • adipinic acid ascorbinic acid and raaleic acid or mixtures thereof .
  • ascorbinic acid and raaleic acid or mixtures thereof e.g. from citric acid, glacial acetic acid, phosphoric acid, tartaric acid, malic acid, fumaric acid, adipinic acid, ascorbinic acid and raaleic acid or mixtures thereof .
  • the pharmaceutically acceptable acid is preferably water-free and can mainly be selected e.g. from citric acid, glacial acetic acid,
  • pharmaceutically acceptable acid is one or more water- free fruit acid, preferably anhydrous citric acid.
  • pharmaceutically acceptable acids are preferably adjusted so that a substantial portion (e.g. at least 90 wt . - % ,
  • the hydrated product obtained from the drying reaction is C (OH) 2 and/or Mg(OH) 2 or a hydrated alkaline earth metal salt of Ca and/or Mg of a pharmaceutically acceptable acid.
  • the self -drying reaction using e.g. MgO as the excipient in the presence of water- free citric acid may be represented as follows :
  • the molar ratio of MgO and citric acid used should be 3:2. In most cases, however, it will not be necessary to convert the entire MgO to g citrate and it will be acceptable that the final formulation still contains some unreacted earth alkaline me al hydroxide . Therefore, higher molar ratios of MgO and citric acid than 3:2 may also be used, such as e.g. 4:2 or 3:1.
  • alkaline metal carbonate or an earth alkaline metal carbonate to the formulations of the present invention, but these carbonates do not act as water- accepting agents, but as disintegration enhancers in the acidic stomach j uices .
  • a pourable or kneadable mass of the self-drying dosage form according to the present invention contains a syrup of one or more pharmaceutically acceptable water-donor (s) , selected from sugars, sugar alcohols or salts , or mixtures thereof .
  • the sugars , sugar alcohols and salts have a water solubility of at least 50%, which means that at least 50 g of the sugar, sugar alcohols or salts or mixtures thereof are soluble in
  • the water-donor as used in the present invention has a ratio of excipient to water at the processing temperature of at least 60:40, preferably from 70:30 up to 90:10, more preferably between 75 : 25 and 85 : 15 and most preferably around 80:20 ( ⁇ 3 parts by weight) .
  • Saccharose for example forms an aqueous solution in water at 20 °C that contains 66.7 parts by weight of saccharose in 33 . 3 parts by weight of water.
  • Sorbitol which forms a 82:18 solution in water at 35°C and a 66.7:33.3 solution in water at 25 °C is even more preferred.
  • Such weight ratios generally afford sufficiently viscous , but not too viscous solutions with which sufficient amounts of water can be introduced so that a pourable or kneadable wet mass can be formed that can then be illed into suitable moulds and chemically dried to obtain a solid casting within short time .
  • Mixtures of several sugars and/or sugar alcohols may also be used in the present invention .
  • such mixtures have a higher solubility in water that either of their components alone .
  • inverted sugar syrup has a higher solubility in water that either glucose or fructose and may therefore be preferred ever at least glucose .
  • Other useful mixtures include hydrogenated starch hydrolysates containing a mixture of sugar alcohols such as maltitol and sorbitol .
  • the commercially available syrup Karion ® 70 is used, consisting of 70 g of sorbitol and 30 g of water. If Karion ® 70 is used as a wa er-donor and CaO and/or MgO as a water-acceptor, a ratio of 40-100 parts by weight of Karion ® 70 to 8-30 parts by weight of CaO and/or MgO, preferably a ratio of 60-80 parts by weight of Karion ® 70 to 15-20 parts by weight CaO and/or MgO, is particularly usef l .
  • a highly concentrated syrup which is both still fluid and contains relatively little water
  • the time for the self - drying in situ can be fine-tuned and is thus superior over the use of pure water.
  • the dehydrat on can thus be adjusted to the required speed of the dosing of the kneadable or pourable pharmaceu ical dosage form into the moulds or packaging. This allows for exam le to even dose bigger charges into moulds or packaging without being at the risk of an untimely and complete self-drying prior to the completion of the dosing .
  • the process for preparing a self -drying dosage form thus comprises the following steps of:
  • preparing a pourable or kneadable mass comprising (i) at least one pharmaceutically acceptable water- donor (s) selected from a syrup of one or more pharmaceutically acceptable sugar ( s) , sugar
  • the drying in situ mainly takes place after the completion of the dosing step (2) .
  • the dosage form is for pharmaceu ical use, it will further contain at least one active pharmaceutical ingredient . It may also contain other pharmaceutically acceptable excipients , such as inert fillers, etc .
  • kneadable mass is dosed is optionally pre- treated with a release or antisticking agent .
  • the release agent is
  • Example for release agents which may be used in the present invention are : Melissa oil , Eucalyptus oil , Miglyol ®
  • caprylic/capric triglycerides Neutralol EuAB
  • castor oil hydrated castor oil
  • bee wax hard fat EuAB (adeps solidus) or mixtures thereo
  • a mixture of 3 parts (by weight) of the wa -like hydrated castor oil , and 6 parts (by weight) of a spreading oils such as Miglyol ® is used as a mould release agent .
  • the releasing agents may be liquefied prior to application by heating or by dissolving in a suitable organic solvent such as ethyl acetate .
  • the moulds or packagings are normally immediately closed or sealed to avoid contamination .
  • a blister paper or plastic foils are normally used for sealing.
  • moisture - tight blisters an aluminium foil is used.
  • the present invention is directed to a solid pharmaceutical dosage form, which is a non-porous casting, comprising at least one active pharmaceutical ingredient and at least one hydrated pharmaceutically acceptable excipient .
  • a solid pharmaceutical dosage form which is a non-porous casting, comprising at least one active pharmaceutical ingredient and at least one hydrated pharmaceutically acceptable excipient .
  • acceptable excipient comprises an alkaline earth metal hydroxide selected from Ca (OH) 2 and/or Mg (OH ) 2 or a hydrated alkaline earth metal salt of Ca and/or Mg of a
  • pharmaceutically acceptable excipient is the reaction product of water and the wate -acceptor used to form the self-drying dosage form according to the present invention.
  • pharmaceutical dosage form according to the present invention may be any organic or inorganic, preferably organic active pharmaceutical ingredient (API) or a
  • the API can be suitably pre- treated to avoid such incompatibilities , e.g. by coating .
  • the solid self-drying pharmaceutical dosage form of the present invention may further comprise one or more additional pharmaceutically acceptable exci ients such as e.g. diluents, binding agents, absorption enhancers , buffers , acids, coatings , disintegrants (such as carbonates or hydrogen carbonates, e.g. sodium carbonate) , surfactants , moisturizing agents , structural builders (e.g. calcium phosphates or calcium sulphates) , sweeteners , and flavorings etc .
  • additional pharmaceutically acceptable exci ients such as e.g. diluents, binding agents, absorption enhancers , buffers , acids, coatings , disintegrants (such as carbonates or hydrogen carbonates, e.g. sodium carbonate) , surfactants , moisturizing agents , structural builders (e.g. calcium phosphates or calcium sulphates) , sweeteners , and flavorings etc .
  • exci ients such as e
  • the solid self-drying pharmaceutical dosage form of the present invention contains a pharmaceutically
  • Suitable amounts of acid range from 0 to 20 wt.%, preferably 0 to 15 wt . % , more preferably 0.1 to 15 wt.%, even more preferably 0.2 to 10 wt.%, still more preferably 1 to 5 wt.%, and most preferably 1.5 to 2.5 wt . 3 ⁇ 4 based on the total weight of the dosage form .
  • Preferred acids for such use are citric acid (preferably anhydrous citric acid) , glacial acetic acid, tartaric acid, but other pharmaceutically acceptable acids as mentioned above may also be used.
  • the solid pharmaceutical dosage form of the present inven ion is for oral administration.
  • pharmaceutical dosage form of the present invention is a casting in a blister pack .
  • the final dosage forms according to the present invention do not exhibit porous structures like they exist in conventional tablets or granulates, but have a very homogenous structure consisting of sugars or sugar alcohols and hydrated salts/hydroxides which are fused together .
  • the castings can have a soft caramel-like to hard glassy
  • the final dosage forms according to the present invention are free from non-biodegradable polymers such as polyethylene oxides or PVP .
  • Preferred dosage forms of the present invention do also not contain a wax or polymer matrix in which the active ingredient is embedded .
  • the present final dosage forms contain 80% or more, more preferably 90% or more, and most preferably 95% or more (based on the total weight of the final dosage form) of ( i ) sugars and/or sugar alcohols and ( ii) hydrated salts and/or hydroxides .
  • Poloxamer 188 0.1 g Poloxamer 188 , 0.4 g aspartame, and 30.0 g mannitol are homogenously suspended in 90.0 g of a 70% aqueous sorbitol syrup (Karion 70 ) while gently heated. After cooling down to room temperature, 100.0 g of acetylsalicylic acid (ASS ) are added to the obtained mixture . Subsequently, 28,5 g of finely ground CaO is added followed by the addition of 1.0 g of glacial acetic acid. Finally, 0.5 g of Melissa oil is added to and homogenously distributed w thin said mass .
  • AVS acetylsalicylic acid
  • the homogeneous mass is dosed in single dosages having a weight of 250 mg per dosage unit and cast into the cavities of a blister packaging that has been pretreated with silicone oil as a mould- release agent .
  • Each casting contains 100 mg of the ac ive ingredient ASS .
  • the blister packaging is sealed with standard aluminium foil for blisters and the sealed dosage form is allowed to dry in situ by storing at room
  • Poloxamer 188 0.15 g aspartame, 0.2 g acesulfame and 25.6 g mannitol are homogenously suspended in 50 g of a warm solution of a 70% sorbitol syrup in water.
  • diclofenac lysinate and 2.0 g peppermint oil are added to this suspension.
  • 10.0 g MgO is added to this suspension.
  • 2.0 g tartaric acid is added .
  • the mass is dispensed into blister cavities in single dosages of each 100 mg total weight by using a suitable dosage device .
  • the obtained dosage form contains 10 mg of the active ingredient .
  • the blister is sealed with aluminium foil and stored at room temperature , while the mass is allowed to dry in situ.
  • eucalyptus oil are homogenously incorporated.
  • the single dosages of each 500 mg are filled into blister cavities using a suitable dosage device .
  • the blister has been pretreated wi h a suitable mould release agent . After 2 - 3 days the castings have become solid and can easily be removed f om the blister packaging .
  • 0.2 g Poloxamer 188 , 0.4 g of aspartame , 13.4 g of manni ol , 4.0 g of Tadalafil , 10 g of finely ground CaO, 2.0 g of MgO and 10.0 g of co fee powder are added to 40.0 g of a 70% aqueous warm saccharose syrup until the mass is evenly coloured.
  • Example 6 Vardenafil Castings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une forme posologique pharmaceutique auto-séchante et un procédé pour sa fabrication. Le procédé implique la liaison de l'eau fournie par un sirop d'un ou de plusieurs sucre(s), alcool(s) de sucre(s) ou sel(s) pharmaceutiquement acceptable(s) ou de mélanges de ceux-ci, utilisés, afin de fabriquer le mélange, par un accepteur d'eau adapté, sélectionné entre CaO et/ou MgO et formant un hydrate stable à température ambiante. Le procédé selon l'invention permet de former directement des éléments moulés prêts à l'emploi sans participation de quelconque étapes de séchage physique, compression ou extrusion. Le procédé permet en outre une application à l'échelle industrielle, étant donné que le temps de séchage et que la vitesse de séchage peuvent être réglés et ajustés finement en faisant varier le choix ou la proportion de l'accepteur d'eau et par l'ajout éventuel d'un acide pharmaceutiquement acceptable.
PCT/EP2015/056079 2014-05-21 2015-03-23 Forme posologique auto-séchante avec temps de séchage et vitesse de séchage réglables Ceased WO2015176848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169261 2014-05-21
EP14169261.6 2014-05-21

Publications (1)

Publication Number Publication Date
WO2015176848A1 true WO2015176848A1 (fr) 2015-11-26

Family

ID=50771108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/056079 Ceased WO2015176848A1 (fr) 2014-05-21 2015-03-23 Forme posologique auto-séchante avec temps de séchage et vitesse de séchage réglables

Country Status (1)

Country Link
WO (1) WO2015176848A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (fr) * 1964-12-04
US4609543A (en) * 1983-11-14 1986-09-02 Nabisco Brands, Inc. Soft homogeneous antacid tablet
US5637313A (en) * 1994-12-16 1997-06-10 Watson Laboratories, Inc. Chewable dosage forms
US6083527A (en) * 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
US6517886B1 (en) * 1997-06-24 2003-02-11 Biovail Corporation International Positive hydration method of preparing confectionery and the resulting product
US20060165759A1 (en) * 2005-01-27 2006-07-27 Warner-Lambert Company Llc Antacid lozenge containing micronized particles
US20070190116A1 (en) * 2005-11-01 2007-08-16 Rigel Technology Corporation Solid calcium bolus product with quick dissolution
US20080014290A1 (en) * 2006-07-12 2008-01-17 Jones Thomas L Composition and Method of Treating a Sore Throat

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (fr) * 1964-12-04
US4609543A (en) * 1983-11-14 1986-09-02 Nabisco Brands, Inc. Soft homogeneous antacid tablet
US5637313A (en) * 1994-12-16 1997-06-10 Watson Laboratories, Inc. Chewable dosage forms
US6517886B1 (en) * 1997-06-24 2003-02-11 Biovail Corporation International Positive hydration method of preparing confectionery and the resulting product
US6083527A (en) * 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
US20060165759A1 (en) * 2005-01-27 2006-07-27 Warner-Lambert Company Llc Antacid lozenge containing micronized particles
US20070190116A1 (en) * 2005-11-01 2007-08-16 Rigel Technology Corporation Solid calcium bolus product with quick dissolution
US20080014290A1 (en) * 2006-07-12 2008-01-17 Jones Thomas L Composition and Method of Treating a Sore Throat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G A EBY III: "Zinc lozenges as cure for the common cold-A review and hypothesis", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 74, no. 3, 1 March 2010 (2010-03-01), pages 482 - 492, XP026892024, ISSN: 0306-9877, [retrieved on 20091110], DOI: 10.1016/J.MEHY.2009.10.017 *

Similar Documents

Publication Publication Date Title
ES2265439T3 (es) Formulacion oral de valdecoxib que se desintegra rapidamente.
Bandari et al. Orodispersible tablets: An overview
Prateek et al. Fast dissolving tablets: a new venture in drug delivery
JP5352474B2 (ja) 口腔内崩壊錠およびその製造方法
EP2797587B1 (fr) Comprimé très robuste à délitement rapide et son procédé de fabrication
KR100421264B1 (ko) 부형제
AU2009284011B2 (en) Sore throat compositions
US6063821A (en) Transparent rapid release compositions of non-steroidal analgesics
BRPI0709909A2 (pt) tabletes de desintegraÇço oral
US7208175B2 (en) Process for the production of rapidly disintegrating, solid pharmaceutical preparations
HU228864B1 (en) Flash-melt oral dosage formulation
Singh et al. Fast dissolving drug delivery systems: formulation, preparation techniques and evaluation
CN101987082A (zh) 固体制剂及其制备方法
AU2006220100B2 (en) Pharmaceutical forms with improved pharmacokinetic properties
KR102092002B1 (ko) 코팅이 있는 정제 및 이의 제조
CZ412099A3 (cs) Způsob přípravy pastilek s obsahem flurbiprofenu
JP6488003B2 (ja) 安定なモンテルカスト溶液
ES2308566T3 (es) Fabricacion de una presentacion rapidamente desintegrable, a partir de un solido en polvo, y una etapa de liofilizacion.
KR20130076511A (ko) 환경에 민감한 약물에 적합한 속붕정 및 이의 제조 방법
WO2015176848A1 (fr) Forme posologique auto-séchante avec temps de séchage et vitesse de séchage réglables
JP2022547514A (ja) 速固結性化合物
Chawla et al. Mouth dissolving tablets: An overview
JP6114573B2 (ja) ロキソプロフェンナトリウムと制酸剤を含有する固形製剤
TW200948398A (en) Vancomycin hydrochloride tablet
Gupta et al. Novel study in fast dissolving drug delivery system: a review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15712856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15712856

Country of ref document: EP

Kind code of ref document: A1